Back to User profile » Dr Haitao Zhao
Papers published by Dr Haitao Zhao:
Adjuvant TACE Improves Prognosis After Resection in Dual-Phenotype Hepatocellular Carcinoma: A Propensity Score-Matched Study
Leng Z, Zhu T, Huang Z, Chen X, Lu Y, Zhang Y, Wan X, Yang X, Zhang L, Zhao H, Du S, Zhao Z, Zheng Y
Journal of Hepatocellular Carcinoma 2025, 12:2213-2224
Published Date: 30 September 2025
Combined TACE with Targeted and Immunotherapy versus TACE Alone Improves DFS in HCC with MVI: A Multicenter Propensity Score Matching Study
Chen X, Wu X, Peng W, Liu L, Liu X, Wan X, Xu H, Zheng Y, Zhao H, Mao Y, Lu X, Sang X, Chang X, Zhou K, Pan J, Guan M, Hu D, Tan H, Zhang Y, Du S
Journal of Hepatocellular Carcinoma 2025, 12:561-577
Published Date: 19 March 2025
The Influence of Visceral Adiposity on Overall Survival: Exploring “Obesity Paradox” Among Hepatocellular Carcinoma Patients Who Receiving Immunotherapy
Zhou Y, Ouyang J, Yang H, Wang Z, Yang Y, Li Q, Zhao H, Zhou J, Li Q
Journal of Hepatocellular Carcinoma 2024, 11:1193-1206
Published Date: 24 June 2024
Adjuvant Lenvatinib Plus PD-1 Antibody for Hepatocellular Carcinoma with High Recurrence Risks After Hepatectomy: A Retrospective Landmark Analysis
Ouyang J, Wang Z, Yuan K, Yang Y, Zhou Y, Li Q, Yang N, Zhao H, Zhao H, Zhou J
Journal of Hepatocellular Carcinoma 2023, 10:1465-1477
Published Date: 6 September 2023
Metabolic Tumor Volume Measured by 18F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents
Wang X, Yang X, Wang J, Dong C, Ding J, Wu M, Wang Y, Ding H, Zhang H, Sang X, Zhao H, Huo L
Journal of Hepatocellular Carcinoma 2023, 10:587-598
Published Date: 8 April 2023
Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study
Chen B, Lei J, Zhao H, Dong J, Zeng Z, Li Y, Yu L, Zhou L, Jia A, Lu Y, Cheng J
Journal of Hepatocellular Carcinoma 2022, 9:1171-1185
Published Date: 8 November 2022
Preoperative Immune Prognostic Index Can Predict the Clinical Outcomes of Patients with Gallbladder Cancer: Single-Center Experience
Sun L, Wang D, Zhang M, Jin Y, Jin B, Xu H, Du S, Xu Y, Zhao H, Lu X, Sang X, Zhong S, Yang H, Mao Y
Cancer Management and Research 2020, 12:12137-12150
Published Date: 25 November 2020
Unleashing The Potential Of Multiple-Targeted Therapies In Hepatobiliary Cancers: Two Cases, Cocktail Therapy With Nine Molecular Targeted Agents And Long-Lasting Survival
Lin J, Yang X, Xie Y, Zhao H
OncoTargets and Therapy 2019, 12:9941-9945
Published Date: 19 November 2019
Preoperative neutrophil–lymphocyte and platelet–lymphocyte ratios as independent predictors of T stages in hilar cholangiocarcinoma
Huang H, Wan X, Bai Y, Bian J, Xiong J, Xu Y, Sang X, Zhao H
Cancer Management and Research 2019, 11:5157-5162
Published Date: 4 June 2019
Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis
Xiong JP, Xu WY, Bian J, Huang HC, Bai Y, Xu YY, Lu X, Zhao HT
Cancer Management and Research 2018, 10:4095-4104
Published Date: 1 October 2018
Metabolic syndrome and the risk of cholangiocarcinoma: a hospital-based case–control study in China
Xiong J, Lu X, Xu W, Bai Y, Huang H, Bian J, Zhang L, Long J, Xu Y, Wang Z, Zhao H
Cancer Management and Research 2018, 10:3849-3855
Published Date: 24 September 2018